Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 96.5% in August

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the target of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 1,646,299 shares, a growth of 96.5% from the July 30th total of 837,868 shares. Approximately 7.6% of the shares of the company are sold short. Based on an average trading volume of 33,615,368 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Valion Bio, Inc. Common Stock presently has a consensus rating of “Sell”.

Valion Bio, Inc. Common Stock Price Performance

Shares of NASDAQ:VBIO opened at $0.12 on Friday. Valion Bio, Inc. Common Stock has a one year low of $0.11 and a one year high of $3.21. The stock has a market capitalization of $2.68 million, a price-to-earnings ratio of -0.02 and a beta of 1.85. The company has a 50-day simple moving average of $0.35 and a 200-day simple moving average of $0.71. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.86 and a current ratio of 1.11.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last released its quarterly earnings results on Friday, August 14th. The company reported ($2.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($408.00) by $405.83.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Valion Bio, Inc. Common Stock stock. Foster & Motley Inc. purchased a new position in shares of Valion Bio, Inc. Common Stock (NASDAQ:VBIO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,728 shares of the company’s stock, valued at approximately $2,715,000. Foster & Motley Inc. owned about 1.29% of Valion Bio, Inc. Common Stock at the end of the most recent reporting period. Institutional investors own 4.25% of the company’s stock.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.